Skip to main content
x

Recent articles

Lilly joins the folate receptor arena

Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.

Merck joins the TIGIT pivotal failure club

Keyvibe-010 fails, but not for the reason you might have expected.

MacroGenics gets that sinking feeling

Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six months’ share price gains.

FDA green and red lights: April 2024

A tumour-agnostic label for Enhertu leads April’s US oncology approvals.

CytomX delivers a pancreatic surprise

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Calliditas puts a brave face on setanaxib failure

A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.